Text Size
209 studies found for:    "Adenocarcinoma of lung"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"Adenocarcinoma of lung"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
Conditions: Adenocarcinoma of Lung Stage IIIB;   Adenocarcinoma of Lung Stage IV
Intervention: Drug: NOV120101 (Poziotinib)
2 Unknown † Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
3 Recruiting Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Conditions: Lung Adenocarcinoma;   Brain Metastases
Interventions: Drug: erlotinib;   Drug: pemetrexed;   Drug: cisplatin
4 Recruiting Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
Conditions: Non-small-cell Lung Cancer;   Squamous Cell Carcinoma;   Adenocarcinoma of the Lung
Interventions: Drug: AXL1717;   Drug: Docetaxel
5 Recruiting Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
Condition: Lung Adenocarcinoma
Intervention: Other: CT, PET, copy number alteration
6 Recruiting The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar
Condition: Advanced Primary Lung Adenocarcinoma
Intervention: Drug: endostar
7 Completed Study of EC145 in Patients With Progressive Adenocarcinoma of the Lung
Condition: Adenocarcinoma of the Lung
Intervention: Drug: EC145
8 Active, not recruiting A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung
Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab;   Other: Placebo;   Drug: Platinum Containing Doublet
9 Completed Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Condition: Lung Adenocarcinoma
Intervention: Drug: erlotinib along with cetuximab
10 Recruiting Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
Condition: KIF5B-RET-Positive Adenocarcinoma of the Lung
Intervention: Drug: Lenvatinib
11 Unknown † Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma
Condition: Lung Adenocarcinoma
Intervention:
12 Active, not recruiting Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: Hsp90 inhibitor AUY922;   Other: laboratory biomarker analysis;   Procedure: needle biopsy;   Genetic: mutation analysis;   Other: pharmacological study
13 Recruiting Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Recurrent Non-small Cell Lung Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: acetylsalicylic acid;   Other: laboratory biomarker analysis
14 Completed Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
Conditions: Pneumonic-type Adenocarcinoma (P-ADC);   Lung Adenocarcinoma With Bronchiolo-alveolar Feature
Intervention: Drug: Gefitinib
15 Active, not recruiting Erlotinib With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: paclitaxel;   Drug: carboplatin
16 Recruiting A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Conditions: Non-Small-Cell Lung Adenocarcinoma;   Non-small Cell Lung Cancer Stage IIIB;   Non-small Cell Lung Cancer Stage IV;   Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Arm A: single agent docetaxel;   Drug: Arm B: Combination of ganetespib and docetaxel
17 Completed Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Condition: Lung Cancer
Intervention: Drug: sorafenib
18 Recruiting Neoadjuvant Pemetrexed, Cisplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma
Condition: Lung Cancer
Intervention: Drug: Neoadjuvant Bevacizumab
19 Recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Condition: Cancer
Intervention: Drug: SNX-5422
20 Recruiting Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
Conditions: Non Small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Gefitinib;   Drug: Placebo;   Drug: Pemetrexed plusCIsplatin
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years